Powerful myeloma treatment regimen shows promise for AL amyloidosis

Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal protein in critical organs of the body, including the kidneys, heart, liver, and intestines, and shares some characteristics with MM.

The combination of , cyclophosphamide, and dexamethasone (CyBorD, or CVD) is a recently discovered but already widely used MM that produces rapid and profound responses. Because of its success in MM, recent investigations have explored the use of this regimen as a potential therapy for AL amyloidosis, since those with the disease have few treatment options. Currently, the most effective treatment for AL amyloidosis is high-dose and autologous stem cell transplant; however, most patients are ineligible for this aggressive and difficult to tolerate approach due to organ damage common in patients with the disease.

Fortunately for AL amyloidosis patients, there is hope for a better treatment. Each of the studies summarized below conclude that treatment with the novel CyBorD/CVD regimen can lead to complete hematologic response and may allow AL amyloidosis patients to become eligible for stem cell transplants and live longer, higher quality lives.

STUDY 1: Cyclophosphamide-Bortezomib-Dexamethasone (CYBORD) Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis
First Author: Joseph Mikhael, MD, Mayo Clinic, Scottsdale, AZ


Retrospective analysis of 17 patients with confirmed and symptomatic AL amyloidosis treated with CyBorD prior to autologous stem cell transplant (ASCT), as an alternative to high-dose therapy for those deemed ineligible, and as salvage for those with prior therapy

94% hematologic response rate observed in patients
Three patients originally not eligible for ASCT became eligible after treatment

CyBorD produces rapid and complete hematologic responses in the majority of patients with AL amyloidosis regardless of previous treatment or ASCT candidacy and is well tolerated with few side effects. In addition, results demonstrate that the regimen may also allow ASCT non-eligible patients to become eligible after treatment.

STUDY 2: Cyclophosphamide, Bortezomib and Dexamethasone Therapy in AL Amyloidosis is Associated with High Clonal Response Rates and Prolonged ProgressionFree Survival
First Author: Christopher Venner, MD, National Amyloidosis Centre, University College London Medical School, London, United Kingdom


of 43 patients with AL amyloidosis treated with CVD upfront or at relapse

81.4% hematologic response rate observed in patients

CVD is a highly effective combination for the treatment of AL with high hematologic responses. In addition, rapid improvement in organ function was observed and functional organ improvement may potentially allow deferred in previously ineligible patients due to increased organ response.

More information: bloodjournal.hematologylibrary… blood-2011-11-390930
bloodjournal.hematologylibrary… blood-2011-10-388462

Related Stories

One step closer in finding treatment for amyloidosis

date Oct 21, 2010

University College London scientists funded by the Medical Research Council (MRC) have devised a new approach to treatment of amyloidosis, according to new research published yesterday in Nature.

Recommended for you

Old cancer drug could have new use in fighting cancer

date 27 minutes ago

A drug used for decades to treat leukemia may have other uses in the fight against cancer, researchers at the University of Missouri have found. Previously, doctors used 6-Thioguanine, or 6-TG, as a chemotherapy ...

Cancer prevention efforts in the US a mixed bag

date 12 hours ago

While there has been substantial progress in some cancer control efforts in the past several decades, like reductions in smoking and increased utilization of cancer screening, progress in some areas is lagging, according ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.